Technical Article
Predicting Physical Stability of Amorphous Solid Dispersions (ASD)
12 Feb 2026
en
Join Crystal Pharmatech Subject Matter Expert, Ridwan Islam, M. Pharm., Ph.D., at MIDD+ Boston, hosted by Simulations Plus, Inc. on May 6-7.
Register for scientific presentations and hands-on learning at: https://lnkd.in/eUefupXz
Utility of PBPK Modeling as Step 1 in a 3-Step First Time Right Crystal Pharmatech Formulation
Abstract:
PBPK modelling is a valuable tool to address a much wider range of pharmaceutical applications besides drug-drug interactions. We present here PBPK modeling applications routinely used at our CDMO for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species in addition to first-in-human pharmacokinetic predictions.
Linking of in-silico quantitative structure–property relationship models with (PBPK) modelling is Step 1 of a tailored Formulation for Phase I. Combined with parameter sensitivity we can clearly identify the key compound API Form and Formulation properties.
This leads to the fastest, most efficient formulation development with visibility into future clinical trials.
Ready for an evening of unscripted connection?
Please complete the form to register for our San Diego Biotech and Pharma R&D social. Note: Registration is subject to review. You will receive a formal confirmation email once your attendance is approved.
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your registration. The information you submit will be governed by our Privacy Policy.
_.webp "A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs")
Subscribe to be the first to get the updates!
